Merck’s Keytruda approved for fourth gynecologic cancer indication
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Subscribe To Our Newsletter & Stay Updated